SCHEMBL4823474

SCHEMBL4823474

O=C(O)c1ccc2cc3n(c2c1)C=COc1ncccc1-3

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 2/20 0.34
KDM4C Q9H3R0 2/20 0.34
KDM6B O15054 1/20 0.34
KDM4A O75164 1/20 0.34
KDM5C P41229 1/20 0.34
KDM2A Q9Y2K7 1/20 0.34
KDM3A Q9Y4C1 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
RORC P51449 3/20 0.33
FGFR1 P11362 2/20 0.33
P4HA1 P13674 1/20 0.33
PKM P14618 1/20 0.33
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
JAK2 O60674 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826983 0.78 SLC40A1 (0.36) POLBSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL4831483 0.71 SMN1; SMN2 (0.36) POLBSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL3244153 0.70 SRD5A2 (0.43) POLBMEN1KMT2AKDM4EKDM4C
SCHEMBL4148741 0.70 KMT2A (0.38) POLBMEN1KMT2AKDM4EFGFR1
SCHEMBL3075059 0.70 TBXA2R (0.36) POLBKMT2AKDM4EHSD17B10ACLY
SCHEMBL4139797 0.69 KMT2A (0.37) POLBMEN1KMT2AKDM4EFGFR1
SCHEMBL4825624 0.68 CA12 (0.35) POLBSMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL4823385 0.68 RPS6KA3 (0.41) SLC40A1FGFR1RAB9AJAK2JAK1
SCHEMBL4830030 0.67 SLC22A12 (0.35)
SCHEMBL4823794 0.66 SMN1; SMN2 (0.37) POLBSMN1; SMN2MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348425-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-25 US disclosed
WO-2007092000-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2007-08-16 WO disclosed
EP-1776368-A1 INHIBITORS OF HCV REPLICATION Bristol-Myers Squibb Company (US) 2007-04-25 EP disclosed
US-7153848-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-26 US disclosed
US-20060166964-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-07-27 US disclosed
US-20060046983-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-03-02 US disclosed
WO-2006020082-A1 INHIBITORS OF HCV REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166964-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 POLB 89/4885SMN1; SMN2 4394/4885MEN1 4615/4885
US-20060046983-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 POLB 89/4885SMN1; SMN2 4394/4885MEN1 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.